Pharmaxis Ltd ( (AU:SNT) ) has issued an update.
Syntara Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO Gary Phillips will present the company’s advancements. The presentation will highlight Syntara’s ongoing projects, including the development of SNT-5505 for myelofibrosis and other drug candidates targeting various diseases. This participation underscores Syntara’s commitment to advancing its drug development pipeline and enhancing its industry presence.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company based in Sydney, Australia, focusing on extracellular matrix dysfunction. It specializes in amine oxidase chemistry to develop novel medicines for blood cancers and conditions related to inflammation and fibrosis. The company has a lead candidate, SNT-5505, for treating myelofibrosis and is also working on other drug candidates targeting fibrotic and inflammatory diseases. Syntara is listed on the Australian Securities Exchange under the code SNT.
YTD Price Performance: -7.50%
Average Trading Volume: 3,674,631
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$118.5M
See more data about SNT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com